Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

NCT01629732 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: Daclatasvir
DRUG: Daclatasvir
DRUG: BMS-986094
DRUG: BMS-986094
DRUG: BMS-986094
DRUG: Ribavirin
DRUG: Placebo for BMS-986094

Sponsor

Bristol-Myers Squibb